3.Vertical transmission of hepatitis B virus: propositions and future directions.
Jin-Feng LIU ; Tian-Yan CHEN ; Ying-Ren ZHAO
Chinese Medical Journal 2021;134(23):2825-2831
Chronic hepatitis B virus (HBV) infection due to vertical transmission remains a critical concern with regards to eliminating HBV infection. Implementation of hepatitis B vaccine, the foundation to prevent perinatal and horizontal transmission, has reduced the prevalence of HBV by >80%. In countries where the hepatitis B immune globulin (HBIG) is available, such as China and the United States, the administration of HBIG and hepatitis B vaccine to the infants of mothers who are positive for hepatitis B surface antigen has become a standard practice and is effective in preventing vertical transmission. Accumulating evidence on the efficacy and safety of antiviral prophylaxis during pregnancy indicates the probability of attaining the goal of the World Health Organization to eliminate hepatitis by 2030. In this review, we discuss the transmission routes, diagnostic criteria, and preventive strategies for vertical transmission. A preventive program that includes screening before pregnancy, antiviral prophylaxis during pregnancy, and postpartum immunoprophylaxis provides "perfect strategies" to eliminate vertical transmission. However, there is still a notable gap between "perfect strategies" and real-world application, including insufficient coverage of timely birth dose vaccine and the efficacy and necessity of HBIG, especially in mothers who are negative for hepatitis B envelope antigen. In particular, there is a clear need for a comprehensive long-term safety profile of antiviral prophylaxis. Therefore, feasible and cost-effective preventive strategies need to be determined across regions. Access also needs to be scaled up to meet the demands for prophylaxis and prevalence targets.
Female
;
Hepatitis B Surface Antigens
;
Hepatitis B Vaccines
;
Hepatitis B virus
;
Hepatitis B, Chronic
;
Humans
;
Infant
;
Infectious Disease Transmission, Vertical/prevention & control*
;
Pregnancy
4.Elimination of hepatitis B virus infection in children: experience and challenge in China.
Jie TANG ; Yu-Qian LUO ; Yi-Hua ZHOU
Chinese Medical Journal 2021;134(23):2818-2824
Chronic hepatitis B virus (HBV) infection is a serious health issue because of its severe sequelae. Prevention of mother-to-child transmission (MTCT) of HBV is critical to eliminate chronic HBV infection. Here, we reviewed the progress toward the elimination of HBV infection in children in China in the recent decade. A universal hepatitis B vaccination program started from 2002 has been intensified, with the coverage of timely birth dose >95% of all newborn infants from 2012. Since 2011, China has taken a nationwide program to administer hepatitis B immunoglobulin (HBIG) with free of charge in all neonates of HBV-infected mothers, leading to a significant increment of timely use of HBIG. The prevalence of hepatitis B surface antigen (HBsAg) was declined from around 10% among children in 1980s to <0.5% among children born after 2011. Administration of oral antiviral agents in HBV-infected pregnant women with HBV DNA >2 × 105 U/mL during the third trimester is increasing, which will further reduce MTCT of HBV. However, there are some challenges in the elimination of HBV infection in children, which need to overcome by the concerted efforts. Nevertheless, it is anticipated that China will achieve the goal set by the World Health Organization that the prevalence of HBsAg in children aged <5 years is ≤0.1% by 2030.
China/epidemiology*
;
Female
;
Hepatitis B/prevention & control*
;
Hepatitis B Surface Antigens
;
Hepatitis B virus
;
Hepatitis B, Chronic/prevention & control*
;
Humans
;
Infant
;
Infant, Newborn
;
Infectious Disease Transmission, Vertical/prevention & control*
;
Pregnancy
;
Pregnancy Complications, Infectious/epidemiology*
5.Consensus on clinical management of hepatitis B virus- infected women of childbearing age.
Chinese Journal of Hepatology 2018;26(3):204-208
The mother-to-child transmission(MTCT) of hepatitis B virus (HBV) is the dominant cause of chronic HBV infection. In order to achieve the goal of "zero" MTCT before pregnancy, during pregnancy, and after pregnancy; standardized management for hepatitis HBV infection in women of childbearing age should be regulated. The content of this consensus includes: screening and treatment of HBV in pregnant women and women of childbearing age, treatment of hepatitis B during pregnancy, preventive measures and evaluation of combined immunization of hepatitis B immunoglobulin and hepatitis B vaccine in newborns, anti-viral therapy for all pregnant women with a high HBV DNA level and post-partum period related management. In addition, 16 recommendations were formed for clinicians to standardize the clinical management of HBV infection in women of child-bearing age.
Child
;
Consensus
;
Female
;
Hepatitis B/virology*
;
Hepatitis B Vaccines/administration & dosage*
;
Hepatitis B virus
;
Hepatitis B, Chronic/prevention & control*
;
Humans
;
Infant, Newborn
;
Infectious Disease Transmission, Vertical/prevention & control*
;
Pregnancy
;
Pregnancy Complications, Infectious/prevention & control*
6.Long-term efficacy of neonatal hepatitis B vaccination against chronic hepatitis B virus infection and chronic liver disease: a cross-sectional study based on Qidong Hepatitis B Intervention Study.
Taoyang CHEN ; Chunfeng QU ; Hongyu YAO ; Lingling LU ; Jian FAN ; Yuting WANG ; Fei HUANG ; Jianhua LU ; Zhengping NI ; Chunsun FAN ; Yawei ZHANG ;
Chinese Journal of Epidemiology 2016;37(1):64-67
<b>OBJECTIVEb>To evaluate the long-term protection efficacy of neonatal hepatitis B vaccination on chronic hepatitis B (CHB) and liver fibrosis and cirrhosis in adults.
<b>METHODSb>From January to October, 2013, a cross-sectional study was conducted among the participants from Qidong Hepatitis B Intervention Study (QHBIS), who were selected through stratified random sampling. The detections of serum alanine aminotransferase (ALT), HBsAg, anti-HBs, anti-HBc, HBeAg, and anti-HBe were conducted and ultrasonography on liver, gallbladder and spleen was performed for them. The positive rates of each serologic markers, the prevalence of active CHB and liver fibrosis and cirrhosis were calculated, the gender specific differences between vaccination group and control group were compared with Chi-square test.
<b>RESULTSb>A total of 4 421 participants aged (25.59±1.84) years in vaccination group and 3 880 participants aged (26.61±2.24) years in control group were surveyed. The positive rates of HBsAg, anti-HBs, anti-HBc, HBeAg and anti-HBe were 2.38%, 37.73%, 3.78%, 0.57% and 2.15% in vaccination group, and 9.02%, 29.41%, 16.83%, 2.73% and 8.87% in control group, respectively, the differences between two groups were statistically significant (all P<0.05). The prevalence of active CHB and liver fibrosis and cirrhosis were 0.45% and 0.16% in vaccination group, 1.29% and 0.39% in control group, the differences between two groups were statistically significant (P<0.05). The active CHB prevalence was lower in females than in males in both vaccination group and control group (P<0.05). The liver fibrosis and cirrhosis prevalence was lower in females than in males in control group (P<0.05); whereas, no statistical significant difference in liver fibrosis & cirrhosis prevalence between males and females was found in vaccination group (P>0.05).
<b>CONCLUSIONSb>Protection conferred by neonatal hepatitis B vaccination could last to marrying age. The gender specific difference in protection efficacy needs further study.
Adult ; China ; Cross-Sectional Studies ; Female ; Hepatitis B Antibodies ; blood ; Hepatitis B Surface Antigens ; blood ; Hepatitis B Vaccines ; therapeutic use ; Hepatitis B virus ; Hepatitis B, Chronic ; prevention & control ; Humans ; Liver Cirrhosis ; Male ; Prevalence ; Vaccination ; statistics & numerical data
7.Comprehensive prophylaxis and treatment of hepatitis B recurrence after liver transplantation.
Acta Academiae Medicinae Sinicae 2005;27(4):431-434
The outcome of liver transplantation for end-stage liver disease secondary to hepatitis B is remarkably impacted by recurrent infection and subsequent allograft failure. Pre-operational viral replication, immunosuppression degree, and disease types play an important role in hepatitis B recurrence. This article summarizes the mechanisms, the influencing factors, and clinical diagnosis for recurrence of hepatitis B following liver transplantation, and discusses multiple strategies to prevent hepatitis B recurrence. Lamivudine in combination with low-dose hepatitis B immuno-globulin currently is the most effective therapy to prevent recurrent hepatitis B virus allograft infection. It is emphasized that effective prophylaxis approaches against hepatitis B virus recurrence should be adopted before, during, and after operation. Long-term and even life-long antiviral therapy is important for a better outcome.
Combined Modality Therapy
;
Hepatitis B Antibodies
;
therapeutic use
;
Hepatitis B virus
;
immunology
;
Hepatitis B, Chronic
;
prevention & control
;
Humans
;
Immunoglobulins
;
therapeutic use
;
Lamivudine
;
therapeutic use
;
Liver Transplantation
;
Postoperative Complications
;
prevention & control
;
Secondary Prevention
8.Chronic hepatitis B in pregnancy: unique challenges and opportunities.
Kumaresan YOGESWARAN ; Scott K FUNG
The Korean Journal of Hepatology 2011;17(1):1-8
Chronic hepatitis B (CHB) affects 350 million individuals worldwide. Perinatal transmission leads to high rates of chronic infection and complications, including cirrhosis and hepatocellular carcinoma. It is important to recognize and appropriately treat CHB in pregnancy, thereby reducing the risk of neonatal transmission and HBV-associated morbidity and mortality. Screening for CHB is recommended in all pregnant mothers as is universal vaccination of infants with hepatitis B virus (HBV) vaccine with or without hepatitis B immunoglobulin (HBIG). This has resulted in a lower incidence of HBsAg seropositivity and HCC in regions where universal infant vaccination has been endorsed. Mode of delivery and breastfeeding do not appear to affect HBV transmission rates based on available data. Overall, CHB does not increase perinatal maternal-fetal mortality. Administration of oral antiviral therapy during the third trimester to HBsAg-positive mothers with HBV DNA> or =7 log IU/mL may be useful in preventing breakthrough infection. Treatment may be considered earlier in pregnancy for persistently active liver disease shown by high ALT, HBV DNA levels and/or significant hepatic fibrosis. Lamivudine, tenofovir and telbivudine are safe and effective and are the agents of choice in pregnancy. However, further clinical studies are necessary to elucidate the role of antiviral therapy in the pregnant HBV carrier.
Antiviral Agents/therapeutic use
;
Female
;
Hepatitis B Surface Antigens/blood
;
Hepatitis B Vaccines/immunology/therapeutic use
;
Hepatitis B, Chronic/prevention & control/*therapy
;
Humans
;
Immunoglobulins/therapeutic use
;
Infectious Disease Transmission, Vertical/prevention & control
;
Pregnancy
;
Pregnancy Complications, Infectious/prevention & control/*therapy
9.Current status of liver diseases in Korea: Hepatitis B.
Hee Bok CHAE ; Jong Hyun KIM ; Ja Kyung KIM ; Hyung Joon YIM
The Korean Journal of Hepatology 2009;15(Suppl 6):S13-S24
Hepatitis B virus (HBV) infection is the one of the most common causes of the liver diseases in Korea. Since the discovery of Australia antigen (hepatitis associated antigen, or HBsAg later), hepatitis associated antigen was tested widely. HBsAg was detected in 6.6~8.6% in 1980's. Later, it decreased to 5.7% in 1990's. Remarkably, seropositivity of the children deceased to 0.2% after the nationwide vaccination program. Although hepatitis B vaccines are highly effective, the failure rate of perinatal prophylaxis in babies born to HBsAg positive mother was reported to be 4.25%. Treatment of chronic hepatitis B was initiated after the introduction of interferon alpha. Lamivudine opened a new era of oral antiviral agent, and it has been widely used in Korea since 1999. Adefovir was proven to have a good efficacy for lamivudine-resistant chronic hepatitis B. Newer potent antiviral agents such as entecavir, clevudine, and telbivudine are available currently. Further studies are warranted for understanding factors influencing natural history, improving treatment outcomes, and overcoming vaccine non-response.
Acute Disease
;
Antiviral Agents/therapeutic use
;
Hepatitis B/diagnosis/drug therapy/*epidemiology/prevention & control
;
Hepatitis B Surface Antigens/analysis
;
Hepatitis B Vaccines/administration & dosage
;
Hepatitis B, Chronic/epidemiology
;
Humans
;
Immunization Programs
;
Korea/epidemiology
;
Seroepidemiologic Studies
10.Activation of anti-HBV immune activity by DNA vaccine via electroporation using heat shock proteins as adjuvant.
Yaxing XU ; Yanzhong WANG ; Bao ZHAO ; Xiaojun ZHANG ; Hongxia FAN ; Xinghui LI ; Songdong MENG
Chinese Journal of Biotechnology 2013;29(12):1765-1775
Although DNA vaccination is now a promising strategy against hepatitis B virus (HBV) infection, this approach has relatively modest antiviral effect, indicating that immunosuppressive mechanisms may occur in the long-term established infection. In this study, we studied the immunogenicity and anti-HBV efficiency of a combination of HBV surface (HBsAg) and core (HBcAg) DNA vaccine, enhanced by heat shock protein (HSP) gp96 or HSP70 and mediated by in vivo electroporation. Immunization with gp96 adjuvanted HBsAg/HBcAg DNA formulation induced potent T cell and antibody immunity against HBsAg and HBcAg. Notably, treatment with gp96 or HSP70 as adjuvant resulted in reduction of Treg populations by around 20%. Moreover, compared with nonimmunized control mice, immunization with gp96 or HSP70 adjuvanted DNA vaccine dramatically decreased serum HBsAg and viral DNA levels, and HBcAg expression in liver. These results may therefore provide an effective strategy for designing gp96-based DNA vaccine for immunotherapy of chronic HBV infection.
Adjuvants, Immunologic
;
Animals
;
Electroporation
;
HSP70 Heat-Shock Proteins
;
immunology
;
Hepatitis B Core Antigens
;
immunology
;
Hepatitis B Surface Antigens
;
immunology
;
Hepatitis B Vaccines
;
immunology
;
Hepatitis B, Chronic
;
prevention & control
;
Immunization
;
Membrane Glycoproteins
;
immunology
;
Mice
;
Mice, Transgenic
;
Vaccines, DNA
;
immunology